Opus Genetics IRD Contract assets and unbilled receivables (Note 10)
Contract assets and unbilled receivables (Note 10) at other companies
Other financials
Where this comes from
Reported directly by Opus Genetics in its filing.
Tagged under the XBRL concept ird:ContractAssetsAndUnbilledReceivablesCurrent.
The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Opus Genetics's contract assets and unbilled receivables (note 10).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Opus Genetics's contract assets and unbilled receivables (note 10)?
- Opus Genetics (IRD) reported contract assets and unbilled receivables (note 10) of $984K in Q1 2026.
- How has Opus Genetics's contract assets and unbilled receivables (note 10) changed year-over-year?
- Opus Genetics's contract assets and unbilled receivables (note 10) decreased by 41.3% year-over-year, from $1.68M to $984K.
- What is the long-term trend for Opus Genetics's contract assets and unbilled receivables (note 10)?
- Over 2 years (2023 to 2025), Opus Genetics's contract assets and unbilled receivables (note 10) has grown at a -8.8% compound annual growth rate (CAGR), from $1.41M to $1.17M.
- What does contract assets and unbilled receivables (note 10) mean?
- This metric represents the value of goods or services transferred to a customer for which the right to consideration is conditional on something other than the passage of time. It captures revenue recognized in advance of formal billing cycles or contractual milestones. Monitoring this balance helps assess the company's ability to convert performance obligations into formal accounts receivable and eventual cash inflows.